The clinical symptoms of all forms of Alzheimer's disease (AD) result from a slowly progressive neurodegeneration that is associated with the excessive deposition of ␤-amyloid (A␤) in plaques and in the cerebrovasculature, and the formation of intraneuronal neurofibrillary tangles, which are composed primarily of abnormally hyperphosphorylated tau protein. The sequence of cellular events that cause this pathology and neurodegeneration is unknown. It is, however, most probably linked to neuronal signal transduction systems that become misregulated in the brains of certain individuals, causing excessive A␤ to be formed and/or deposited, tau to become aggregated and hyperphosphorylated and neurons to degenerate. We hypothesize that a progressive alteration in the ability of neurons to regulate intracellular calcium, particularly at the level of the endoplasmic reticulum, is a crucial signal transduction event that is linked strongly to the initiation and development of AD pathology. In this chapter we will discuss the key findings that lend support to this hypothesis.
Cellular mechanisms proposed to underlie the neurodegeneration of AD: where does calcium fit in?
Calcium (Ca 2ϩ ) has long been implicated as a key life and death signal for neurons [1] and many studies support a key role for deregulated Ca 2ϩ homoeostasis in the neurodegenerative processes of AD [2] [3] [4] . Although it is indisputable that Ca 2ϩ is involved in the neurodegeneration of AD, it has been difficult to evaluate whether dysfunctions in neuronal Ca 2ϩ metabolism are a proximal cause or an associated consequence of the disease pathology. For dysfunctional Ca 2ϩ homoeostasis to be a primary cause of the neurodegeneration of AD, it should occur early on in the disease and have the potential to cause progressive ␤-amyloid deposition, abnormal tau hyperphosphorylation and selective neuronal cell death. Evidence outlined in this chapter indicates that this could be the case. Findings discussed below also support the possibility that dysfunctional Ca 2ϩ homoeostasis is a driving force for AD pathology, secondary to increased A␤, increased C-100 [the 100 C-terminal amino acids of the ␤-amyloid precursor protein (APP)] and/or reciprocal decreased sAPP␣ (a secreted product of APP processing) in the disease. Recent findings have also shown that mutations in presenilin 1 and presenilin 2, which cause familial forms of AD, deregulate intracellular Ca 2ϩ homoeostasis [5] . Together, this data suggests that altered Ca 2ϩ homoeostasis may be a common cellular instigator for neurodegeneration in both sporadic and familial forms of AD
Neuronal Ca 2ϩ homoeostasis
Intracellular Ca 2ϩ ([Ca 2ϩ ]i) is a critical neuronal second messenger playing a vital role in synaptic transmission and the maintenance of neuronal function and survival [1, 5] . Neurons possess elaborately controlled systems for regulating and responding to changes in [Ca 2ϩ ]i because of its crucial and powerful signalling role. (Figure 1 shows a simplified scheme of the mechanisms which control [Ca 2ϩ ]i homoeostasis.) Briefly, intraneuronal Ca 2ϩ is derived from sources both outside and inside the cell. Ca 2ϩ enters the cell through voltage-and ligand-operated ion channels and is also released within the cell from endoplasmic reticulum (ER) stores by activation of Ins(1,4,5)P 3 (IP 3 ) receptors (IP 3 Rs) and ryanodine receptors (RyRs). In general IP 3 Rs respond to IP 3 which is produced through agonist activation of the phosphatidylinositol signalling pathway, whereas RyRs are directly responsive to [Ca 2ϩ ]i, so-called Ca 2ϩ -induced Ca 2ϩ release.
A variety of other proteins play a crucial role in maintaining [Ca 2ϩ ]i homoeostasis. These include: the SERCA (sarcoplasmic/endoplasmic-reticulum Ca 2ϩ -ATPase) pump, which accumulates Ca 2ϩ into the ER; Ca 2ϩ -ATPase and Na ϩ /Ca 2ϩ membrane exchangers in the plasma membrane, which move Ca 2ϩ out of the cell; and Ca 2ϩ -binding proteins which sequester free Ca 2ϩ . The mitochondria also sequester some of the Ca 2ϩ signal and Ca 2ϩ shuttles between the ER and mitochondria. cally cleaved at the cell surface within the A␤ sequence by ␣-secretase generating sAPP␣ and the non-amyloidogenic 3 kDa (p3) A␤ peptide. It has been widely shown that APP processing can be modulated by cell signal transduction pathways including Ca 2ϩ ( [7] ; see also chapter 16). Of interest, firstly with respect to intracellular Ca 2ϩ signalling, is the finding that A␤42 localizes to the ER in neurons but does not appear to do so in other cell types [8, 9] . This suggests that the ER may be an important site for generating A␤42. In agreement with this studies have shown that activation of ER Ca 2ϩ release from RyRs in HEK-293 cells increased total A␤ and p3 secretion fourfold [10] . This effect was potentiated by thapsigargin and cyclopiazonic acid agents which raise [Ca 2ϩ ]i by preventing its reuptake into the ER [10] . Other studies have reported that thapsigargin could either increase or decrease A␤ release, depending on the concentration used, and that it could increase formation of soluble APP (sAPP) from CHO cells overexpressing APP 751 following down-regulation of protein kinase C (PKC) [11] . In contrast to these findings, Nitsch and colleagues did not observe any changes in the levels of sAPP release in 3T3 cells following treatment with thapsigargin [12] . Treatment of cells with the Ca 2ϩ ionophore A23187 has also been shown to up-regulate total A␤ production, this effect appeared to be dependent on extracellular Ca 2ϩ [13] . The exact relationship between the release and uptake of Ca 2ϩ and the processing of APP in the ER remains to be defined, particularly in neurons where APP processing differs from that detected in cell lines of peripheral origin [14] . The mechanism(s) underlying the effect of disrupted ER Ca 2ϩ signalling on APP processing may involve alteration of the exit or export of APP or C-100 from the ER, and/or alteration in the regulation of Ca 2ϩ -dependent cofactors/proteins controlling the secretase enzymes, or indeed direct effects of Ca 2ϩ on the secretase enzymes that cleave APP. In this respect, the regulation of ER Ca 2ϩ release exerted by the presenilin proteins may influence their role in ␥-secretase processing of APP (see section on presenilins).
The influence of A␤, C-100 and sAPP on Ca 2ϩ homoeostasis
A greater quantity of work has focused upon the effects of APP and its metabolites on Ca 2ϩ homoeostasis than on the effect of Ca 2ϩ homoeostasis on APP processing. The overall outcome of this work suggests that overproduction of A␤ and its precursor C-100 or diminished production of sAPP␣ has a primary effect on neuronal Ca 2ϩ homoeostasis. This is proposed to initiate a pathological neuronal cell death cascade that could potentially be inhibited by blocking these detrimental Ca 2ϩ responses. Work examining the effect of A␤ on Ca 2ϩ homoeostasis has been performed in a variety of cell culture systems using a broad array of A␤ types, A␤ preparation methods and A␤ concentrations. Primarily, studies have used micromolar concentrations of A␤40 and A␤25-35 peptides with fewer studies using A␤42. It is still unclear which species of A␤ is neurotoxic, e.g. protofibrils, oligomers or higher-molecularmass species (see chapter 1), and whether the A␤ is only neurotoxic outside the neuron or can be toxic upon intracellular production. Results have shown that A␤ peptides can induce neurotoxicity by increasing [Ca 2ϩ ]i [15] which can involve enhanced excitatory-amino-acid-and Ca 2ϩ -ionophore-induced Ca 2ϩ fluxes [16] [17] [18] . In agreement with this, A␤ peptides have been shown to affect Ca 2ϩ uptake into PC12 cells [19] and cortical and hippocampal neurons [20] . They have also been shown to increase the activity of Ca 2ϩ -channel proteins, including the L-type voltage-operated Ca 2ϩ channels [21, 22] , possibly through mitogen-activated protein (MAP) kinase phosphorylation of the channel [23] , and N-type voltage-gated Ca 2ϩ channels [24] . The IP 3 Ca 2ϩ -release channel has been shown to exhibit enhanced [ 3 H]IP 3 binding in the presence of A␤ peptides [25] and also to mobilize Ca 2ϩ in response to A␤ peptides [26] . The involvement of voltage-operated Ca 2ϩ channels in A␤-induced neurodegeneration is further confirmed by findings that A␤-induced neurodegeneration can be blocked by nimodipine and Co 2ϩ [21, 22] . A␤ peptides have also been found to impair K ϩ -dependent Ca 2ϩ flux [27, 28] and to block Na ϩ /K ϩ -ATPase activity, thus indirectly impairing the removal of excess [Ca 2ϩ ]i by ion-exchange pumps [29, 30] .
The mechanism(s) by which A␤ affects such a range of the cellular Ca 2ϩ signalling machinery and the relevance of the in vitro work to the situation that occurs in vivo is unknown. The observation that A␤40 [31, 32] and A␤42 [33] can insert into synthetic lipid bilayers and reconstituted lipid vesicles as a Ca 2ϩ -carrying ionophore may be important. In this respect the localization of A␤42 to the ER in neurons and the identification of specific binding sites for A␤ in the ER [34] suggest the possibility that A␤42 may disrupt ER Ca 2ϩ homoeostasis by inserting into ER membranes. The exact sequence of signalling events by which A␤-induced increases in [Ca 2ϩ ]i cause neuronal cell death is not entirely clear but it has been proposed to trigger intracellular events that eventually cause cell dysfunction and death, including oxidative stress and activation of apoptotic cell death pathways.
C-100, cleaved from APP by ␤-secretase, which includes the A␤ sequence has also been shown to affect Ca 2ϩ homoeostasis. Studies have shown that PC12 cells expressing C-100 show altered Ca 2ϩ handling [35] and exhibit enhanced sensitivity to the Ca 2ϩ ionophore A23187 [36] , with this peptide also showing the ability to propagate intercellular Ca 2ϩ waves [37] . Further studies have shown that this APP fragment inhibits the Na ϩ / Ca 2ϩ -exchanger activity in SK-N-SH cells [38] and decreases the activity of the Mg 2ϩ /Ca 2ϩ -ATPase of the ER, suggesting that this peptide, which is only found inside neurons, can inhibit the ability of the ER to sequester Ca 2ϩ in AD [39] .
sAPP␣ has also been found to modulate [Ca 2ϩ ]i, where it normalizes [Ca 2ϩ ]i increases induced by cellular insults including A␤. Increases in the second messenger cGMP and its responsive cGMP-dependent kinase [40] , and activation of the transcription factor nuclear factor B (NF-B) [41] , have been shown to be involved in the Ca 2ϩ -normalizing effect of sAPP␣. sAPP␣ has also been found to activate K ϩ channels [42] , an effect that was mimicked by cGMP and that reduced Ca 2ϩ influx [42, 43] , suggesting that activation of K ϩ channels and membrane hyperpolarization may be the primary neuroprotective target of sAPP␣. In summary it is believed that increased production of A␤ in association with decreased production of sAPP␣ will have detrimental effects on the neuronal Ca 2ϩ signalling machinery activating cell death pathways in the AD brain.
Presenilin modulation of Ca 2ϩ homoeostasis
Disrupted Ca 2ϩ homoeostasis may be a common cellular pathway for neurodegeneration both in sporadic and familial forms of AD. This evolves from findings showing that presenilin 1 (PS1) and presenilin 2 (PS2) mutations which cause familial forms of AD, cause disruptions in intracellular Ca 2ϩ homoeostasis which can cause neurodegeneration. The effect of presenilin mutations on Ca 2ϩ homoeostasis primarily targets the ER, affecting both IP 3 Rand RyR-induced Ca 2ϩ release (see chapter 15) . This fits in with the cellular localization of the presenilins, which are detected predominantly in the ER [44] [45] [46] . Results have shown that familial AD-causing PS1 mutations enhance Ca 2ϩ release in a variety of systems including: cells transfected with PS1 mutants [47, 48] ; mutant PS1 knockin mice [49] ; synaptosomes prepared from transgenic mice expressing mutant PS1 [50] ; and fibroblasts from patients with familial AD [51, 52] . Increased [Ca 2ϩ ]i levels and resultant neurotoxic responses to A␤ and other stressors induced by PS-1 mutations could be blocked by dantrolene, an inhibitor of RyR-induced Ca 2ϩ release [47, 48, 50] , suggesting that the neurodegenerative effect induced by PS1 mutations involves disruption of RyR-induced Ca 2ϩ release from the ER. Recent results confirm this and have shown that PS2 interacts with the Ca 2ϩ -binding protein sorcin [53] , a known modulator of RyR activity [54] , which influences the interaction of RyRs with L-type Ca 2ϩ channels [55] , and that RyR expression levels are enhanced by PS1 mutations (see chapter 15). PS1 mutations have also been found to affect the IP 3 receptor, where IP 3 -evoked Ca 2ϩ signals were found to be potentiated significantly by PS1 mutants, in Xenopus oocytes [56] . Furthermore, fibroblasts from patients with PS1 mutations, and PC12 cells transfected with PS1 mutants, exhibit increased Ca 2ϩ release from intracellular stores in response to agonists that activate the phosphatidylinositol signal transduction system [47, 51, 52] .
The importance of ER Ca 2ϩ release in the neurodegeneration of AD is shown by findings which demonstrate that blocking enhanced ER Ca 2ϩ release, particularly with dantrolene which targets the RyR can protect against the neurodegeneration initiated by PS mutations and A␤. The relationship between PS mutant-induced increases in A␤42 production and ER Ca 2ϩ homoeostasis remains to be determined. In this respect it is of importance to investigate whether increased A␤42 production is a cause or consequence of ER Ca 2ϩ -release dysfunction.
Calcium signalling and tau hyperphosphorylation
Tau proteins are the predominant component of the paired helical filaments (PHFs) in intracellular neurofibrillary tangles (NFTs), neuropil threads and neuritic plaques of the AD brain. PHF-tau differs from normal tau by several post-translational modifications, including hyperphosphorylation, altered glycosylation and altered proteolysis. Tau hyperphosphorylation is regarded as the major driving force for PHF formation and severely affects tau function, reducing its ability to bind to and stabilize microtubules, thus leading to disturbances in neuronal microtubular function in the AD brain [57, 58] .
Tau hyperphosphorylation must ensue through deregulation of one or several signal transduction cascades regulating kinases and/or phosphatases targeting tau [57] . However, the cellular mechanisms contributing to phosphorylation of tau to form PHFs in AD are still unclear and appear to be complex. Presently the consensus is that the proline-directed kinases, including: glycogen synthase kinase-3 (GSK-3); cyclin-dependent kinases, cdc(2) (cell division control) and CDK5 (p35): and MAP kinases, extracellular signal-related protein kinase, c-jun N-terminal kinase and p38 MAP kinase, are prominently involved in tau phosphorylation [57] . Of these, GSK-3␤ is believed to be a crucial physiological kinase for tau, and studies have shown that GSK-3 preferentially localizes to NFT-bearing neurons [59] and that the distribution of the active form of the enzyme parallels the spread of AD neurofibrillary changes [60] . Phosphorylation of tau by non-proline-directed kinases also occurs. These include protein kinase A (PKA), myristoylated alanine-rich C-kinase, calcium/calmodulin-dependent kinase II (CaM kinase II), casein kinase I and II and protein kinase C (PKC), some of which have been shown to act synergistically with the proline-directed kinases in the phosphorylation of tau [57] . The protein phosphatases PP2A, PP2B and PP1 also have important roles in the regulation of the phosphorylation state of tau and can dephosphorylate tau that has been phosphorylated by many of the above kinases, converting it to a normal form [61] . It has also been shown that PP2A and PP2B can catalyse tau dephosphorylation in PHFs prepared from AD brains [62] .
Intracellular Ca 2ϩ signals of varying amplitude and frequency are vital regulators of cellular kinase and phosphatases [63, 64] . It is therefore possible that hyperphosphorylation of tau is an event downstream of a primary defect of [Ca 2ϩ ]i homoeostasis. In this respect it has been shown that Ca 2ϩ can control many of the kinases and phosphatases implicated in tau phosphorylation including GSK-3␤, the MAP kinase family, the cyclin-dependent kinases and many of the non-proline-directed protein kinases, particularly PKA, PKC and CaM kinase II, plus the Ca 2ϩ -dependent phosphatase PP2B or calcineurin. Transient increases in [Ca 2ϩ ]i have been shown to cause persistent tyrosine phosphorylation and activation of GSK-3␤ resulting in prolonged site-selective increases in tau phosphorylation [65] . It has also been shown that Ca 2ϩ influx through the N-methyl-D-aspartate (NMDA) receptors dephosphorylates tau [67] . Impaired Ca 2ϩ influx through the NMDA receptor may thus cause tau hyperphosphorylation possibly through down-regulation of the CaM kinase II-Akt-pathway [68] which would cause activation of GSK-3␤.
Results have shown that calcineurin can dephosphorylate tau at select sites [62] and can revert tau that has been phosphorylated in vitro by CaM kinase II, PKA, MAP kinase and cdc(2) kinase to a normal-like state [61] that can bind to microtubules and promote tubulin polymerization. These results suggest that impaired calcineurin activity in the AD brain can lead to neurofibrillary pathology. Ca 2ϩ has been shown to regulate other aspects of tau function other than the kinases and phosphatases that phosphorylate tau. These include the ability to induce aggregates of PHF-tau but not normal human tau [69] , and the proteolysis of tau by calpains [70] .
Studies of the direct effect of altering [Ca 2ϩ ]i on the state of tau phosphorylation within cells have for the most part not investigated the response to changes in the amplitude and frequency of the Ca 2ϩ signal, which plays an important role in mediating phosphorylation-dependent cell function. Rather, these studies have simply totally up-regulated intracellular Ca 2ϩ using agents such as Ca 2ϩ ionophores. These studies have found that the treatment of primary neuronal cultures with Ca 2ϩ ionophores both increases [17, 71] and decreases [72] tau phosphorylation. Ca 2ϩ ionophore treatment of human neuroblastoma cells was also shown to result in both increases [73] and decreases [74] in tau phosphorylation. Further studies have shown that increasing intracellular Ca 2ϩ by activation of NMDA receptors results in the dephosphorylation of tau in rat brain slices [75] and cortical neuronal cultures [72] . More in-depth studies are needed to define which aspects of [Ca 2ϩ ]i signalling control tau phosphorylation, and how this relates to the effects of Ca 2ϩ on APP metabolism.
Ca 2ϩ signal transduction dysfunction in the AD brain
Regulation of [Ca 2ϩ ]i homoeostasis is impaired in the post-mortem AD brain when compared to control brains, which correlates with the in vitro work outlined above. This occurs at a number of levels including alterations in Ca 2ϩ -channel proteins and the status of many Ca 2ϩ -activated enzymes, such as key neuronal proteases, kinases and phosphatases. Prominent among the Ca 2ϩ -channel defects are critical alterations in the IP 3 R and RyR Ca 2ϩ -release channels of the ER, which are affected at very early stages of AD pathology and in the specific brain areas which are damaged in the disease. Work by our groups suggests that a primary, but slowly progressive impairment in the control of Ca 2ϩ release from the ER in AD brain, would have a downstream effect on an array of vital Ca 2ϩ -regulatable systems and on ER function in neurons, thus causing progressive neuronal damage and AD pathology and neuronal loss. Figure 2 shows the proposed model.
IP 3 Rs and RyRs in AD
The activation of IP 3 R and RyR ER Ca 2ϩ -release channels plays a crucial role in regulating diverse Ca 2ϩ signals and an array of neuronal functions such as excitability, release of transmitters, synaptic plasticity, gene expression and neuronal survival, being central to efficient receptor communication and coordination in brain [1] . Disruption of efficient ER Ca 2ϩ release would be expected to have a negative effect on all of the above neuronal functions, many of which are known to be impaired in the AD brain.
The first evidence suggesting that Ca 2ϩ release from the ER was impaired in the AD brain post mortem was provided by Young and colleagues [76] who reported significant reductions in the number of [ 3 H]IP 3 binding sites in homogenates of AD parietal cortex and hippocampus, but not in the frontal, occipital or temporal cortices, when compared to control brains. This study was confirmed by Garlind and colleagues [77] , who detected reduced [ 3 H]IP 3 binding in the same brain regions and also in AD temporal cortex, frontal cortex and cerebellum when compared to matched control brains. Subsequently it was reported that reduced IP 3 R levels in the AD temporal cortex, as determined by immunoblotting (using an antisera that did not discriminate between IP 3 R isoforms), correlated with a semi-quantitative score for neuritic plaque and NFT accumulation [78] . In agreement with this it has been shown that IP 3 R loss in the entorhinal cortex, subiculum and CA1 pyramidal layer of the anterior hippocampus correlated with the staging for both neurofibrillary changes and amyloid deposition [79] . These latter results strongly suggest that progressive loss of IP 3 R and [ 3 H]IP 3 binding sites in AD is linked mechanistically to the development of disease pathology.
Historically RyRs have been little examined in human brain and not at all in neurodegenerative disorders. This has been an oversight as RyRs may be as or more important than IP 3 Rs when considering human brain Ca 2ϩ homoeostasis in AD. This is owing to the presence of RyR, particularly RyR-2, in areas that are susceptible to degeneration in AD [80, 81] and to the fact that the unit conductance for RyR is about 10 times that of IP 3 R. Our group was the first to examine the integrity of the RyR in the AD brain [82] . These studies [84] , is significantly and selectively reduced in brain regions affected by the pathology of AD [85] . This loss of FKBP12 correlates positively with the loss of RyR-2 and [ 3 H]ryanodine binding in the disease ( [85] and M. Carmody, M. Kelliher and C. O'Neill, unpublished work) suggesting that loss of FKBP12 may be linked mechanistically to RyR-2 dysfunction in the disease. Loss of FKBP12 is known to have severe repercussions on RyR function, rendering these calcium channels 'leaky' and unable to exhibit full conductance states [84, 86] , a situation that may thus occur in the AD brain.
Such an alteration in both RyRs and IP 3 Rs as detected in AD would be expected to put the ER under progressive and eventually substantial stress, a phenomenon that has been hypothesized to underlie neuronal degeneration [5] and which will influence vital ER functions including protein folding, secretion, aggregation and export [87] . This impairment of RyR and IP 3 R responses would also severely compromise key neuronal signal transduction pathways that underlie cognitive and higher mental function. Inherent in this is impaired function of the vast array of enzymes and binding proteins that are controlled by temporal and spatial increases in [Ca 2ϩ ]i brought about by RyR and IP 3 R which is discussed in the sections below.
Ca 2ϩ -dependent enzymes in the AD brain
Many key Ca 2ϩ -regulated enzymes have been found to be impaired in AD brain. These include: proteases, including the calpains; kinases, including PKC; CaM kinase II; the phosphatase calcineurin; and oxidative stress-linked enzymes including nitric oxide synthase (NOS) and phospholipase A 2 (PLA 2 ) Other key Ca 2ϩ -regulated signalling molecules such as adenylate cyclase and phospholipase C are also dysfunctional in AD brain and are discussed in chapter 16.
Ca 2ϩ -dependent proteases in the AD brain
One of the most thoroughly studied groups of Ca 2ϩ -dependent proteases are the calpains, which are Ca 2ϩ -activated cysteine proteases. There are two isoenzymes, calpain I and calpain II, which require micromolar and millimolar levels of Ca 2ϩ respectively for full activity in vitro. These proteases regulate protein function by limited proteolysis. Both isoforms have been found to be consistently up-regulated in the brains of patients with AD [88] [89] [90] . Grynspan and colleagues [88] have shown that active calpain II accumulates in NFTs and is an early-appearing pervasive component of the neurofibrillary pathology in the disease. Studies by Tsuji and colleagues [91] have detected significantly increased levels of calpain II in cytosolic fractions from AD brains post mortem when compared to control tissue. It is possible that increased Ca 2ϩ release from RyRs is responsible for calpain II activation in the hippocampus at early stages of AD although this has not been investigated. Calpain II has been shown to be activated at very early stages of neurofibrillary pathology in the entorhinal cortex and hippocampus. This would be consistent with the up-regulation of [ 3 H]ryanodine binding sites observed by us in these regions at early stages in the development of neurofibrillary pathology. Calpain mobilization and its long-term and abnormal activation are believed to be a major contributor to proteolysis and removal of cytoskeletal fragments during NFT formation. It is also believed to play an important role in aggregation events, particularly of the cytoskeleton, while also cleaving and modulating kinases and phosphatases that modulate cytoskeletal proteins including tau.
Calpain activity is thought also to be necessary for apoptotic cell death in certain systems [92, 93] and to proteolytically cleave enzymes and proteins involved in apoptosis. Amongst these are the caspase protease family which are believed to play a key role in apoptotic cell death pathways in the nervous system [92] and have been shown to be regulated by [Ca 2ϩ ]i and calpains [92, 94, 95] . Work is presently emerging to support a role for the caspase protease family in the neurodegeneration of AD [96, 97] . An extensive study of the integrity of these cysteine proteases in the AD brain has not been performed. However, studies have detected a 50-100% elevation in caspase I or interleukin-1␤-converting enzyme (ICE) in the hippocampus of AD brains compared to controls [98] , with overexpression of ICE-␣ cDNA also reported in the AD brain [99] . Furthermore, transcription factors activated by caspase-1, such as NF-B, can be induced by elevated [Ca 2ϩ ]i and drive important responses to neuronal stress. Activated NF-B p65 has been shown to be upregulated in the AD brain [100] where it has been found to associate with the plaque pathology of the disease [101, 102] .
Ca 2ϩ -activated kinases in the AD brain
Central and critical alterations in the PKC family of enzymes have been described in the brains of AD patients. PKC dysfunction has been the most consistent and reported alteration in the phosphoinositide signalling pathway in AD brain and is discussed in detail in chapter 16. Disrupted intracellular Ca 2ϩ homoeostasis may be a driving force for PKC dysfunction in AD as the conventional PKC isoforms (␣, ␤⌱, ␤⌱⌱ and ␥) are regulated by Ca 2ϩ and show reduced activity in AD brain compared to control tissue.
CaM kinase II is one of the most abundant kinases in the brain and has a key role in memory function and synaptic plasticity [103, 104] . This Ca 2ϩ -dependent kinase is widely expressed in neurons vulnerable to AD pathology and has been shown to be differentially modulated in AD, where it is shown to be associated with PHF [105, 106] . The finding that GSK-3␤ is overactive in the brains of AD patients compared to controls, and that the active form of the enzyme co-localizes with NFTs in the disease, suggests that the enzyme is misregulated in AD. This altered regulation may include loss of the normal inhibitory input to GSK-␤ induced by growth factors, wingless (wnt)/␤-catenin signalling and also by CaM kinase II activation, all of which can increase the kinase activity of Akt to phosphorylate and inactivate GSK-3␤.
Ca 2ϩ -dependent phosphatases in the AD brain PP2B or calcineurin is expressed at very high levels in the brain and can dephosphorylate PHF-tau in vitro as mentioned above. Calcineurin has a variety of roles in the nervous system including: the regulation of Ca 2ϩ release from IP 3 R and RyR, neurotransmitter release, synaptic plasticity and neuronal survival/apoptosis. Studies examining calcineurin in the brain post mortem detected a co-localization of calcineurin with NFT and a selective reduction of calcineurin expression in neurons containing NFTs [59] . Furthermore, knockout mice lacking the gene for the calcineurin catalytic subunit show accumulation of phosphorylated tau in the hippocampus [107] . Initial immunoblot analysis did not detect any difference in total levels of calcineurin when comapping homogenates prepared from AD and matched control brains [108, 109] . However, more detailed studies by Ladner and colleagues [110] detected reduced calcineurin activity in the AD brain, which correlated inversely with NFT and neuritic plaque density and which was selective to areas pathologically affected by the disorder.
Ca 2ϩ -activated NOS and PLA 2 in the AD brain
The integrity of Ca 2ϩ -activated enzymes involved in Ca 2ϩ -induced oxidative stress pathways in the brain, including the neuronal and endothelial isoforms of NOS (nNOS and eNOS) and PLA 2 , has been examined in AD brains. NOS has received the most attention, owing to the key role that NO is believed to play in neurodegenerative pathways. Results from investigations examining the integrity of NOS in AD brain have been somewhat contradictory. Thus some investigations have shown nNOS-containing neurons to be susceptible to neurodegeneration, with decreased levels of nNOS detected in the entorhinal cortex and hippocampus of AD brains [111, 112] compared to controls. Whereas other investigations have reported nNOS-containing neurons to be resistant to the neurodegeneration of AD [113] . The eNOS enzyme has been reported to be aberrantly expressed in the AD brain compared to control brain tissue [114] . Studies performed in our group have detected a selective impairment of the nNOS isoform in areas pathologically affected by AD with highly significant reductions in nNOS levels in the presence of unaltered nNOS activity, suggesting a loss of control of this enzyme in AD ( [115] and M. Kenny, R. Ravid and C. O'Neill, unpublished work).
PLA 2 activates the arachidonic acid cascade leading to the generation of multiple eicosanoids, many of which are believed to play a role in the inflammatory process. PLA 2 is activated by very low levels of Ca 2ϩ and thought to control receptor-mediated eicosanoid production. Ross and colleagues have detected significant reductions in PLA 2 activity, both in the presence and absence of Ca 2ϩ in the parietal and temporal cortex of AD brains compared to control brains [116] . On the other hand, Stephenson and colleagues, showed elevations in cytosolic PLA 2 immunoreactivity in AD brains suggestive of the presence of an increased inflammatory response mechanism through this pathway in the disease [117] .
Ca 2ϩ -binding proteins in AD
Ca 2ϩ -binding proteins buffer intracellular Ca 2ϩ levels and regulate many Ca 2ϩ -dependent processes playing a vital role in maintaining efficient Ca 2ϩ homoeostasis in the brain. In general, many of the Ca 2ϩ -binding proteins investigated so far in the AD brain are expressed to much higher levels in interneurons than in pyramidal neurons, the latter being the major neuronal type to degenerate in AD. These Ca 2ϩ -binding proteins include: parvalbumin, calretilin, and calbindin 28K. The general consensus from work performed is that neurons containing these binding proteins are resistant to the neurodegeneration of AD [118] [119] [120] [121] . Some investigations have detected a selective loss of calbindin 28K in specific cortical layers of the AD brain, when compared to control brains [122, 123] , with more recent results also detecting subfield-and layer-specific changes in parvalbumin and calretilin in the entorhinal cortex in AD [124] . A more specific study of the functional integrity and profile of the Ca 2ϩ -binding proteins of pyramidal neurons would be beneficial in elucidating whether changes in the function or expression of these proteins are linked to the Ca 2ϩ -induced neurodegenerative pathways of AD.
Summary and future directions
Disrupted Ca 2ϩ release from the ER, particularly from the RyR, is one of the earliest changes described in neuronal Ca 2ϩ homoeostasis in the AD brain. We believe that slowly progressive impairments in both the RyR and IP 3 R cause the progressive deregulation of a number of critical Ca 2ϩ -dependent enzymes to induce cellular stress leading to the neurodegeneration and pathology of AD. This raises the exciting possibility that targeting these ER Ca 2ϩ channels to negate their malfunction may protect against the neurodegeneration of AD. In the future, experiments examining the role of the RyR, IP 3 R and ER functions in neurodegeneration will be important. In this respect, development of neuronal expression systems, both cell lines and transgenic animals, for normal and genetically modified RyRs and IP 3 Rs will provide valuable information about the role of these receptors in brain function and neurodegeneration.
